FTSE MIB
33.594,54 -286,96 (-0,85%) Dow Jones
37.775,38 +22,07 (+0,06%) Nasdaq
15.601,50 -81,87 (-0,52%) Nikkei 225
37.068,35 -1.011,35 (-2,66%) Petrolio
83,37 +0,64 (+0,77%) Bitcoin EUR
60.753,56 +3.055,29 (+5,30%)
NuCana plc (NCNA)
Dopo ore:
| Chiusura precedente | 3,9700 |
| Aperto | 4,0800 |
| Denaro | 3,6700 x 100 |
| Lettera | 3,8500 x 100 |
| Min-Max giorno | 3,6106 - 4,1793 |
| Intervallo di 52 settimane | 3,6100 - 23,7500 |
| Volume | |
| Media Volume | 71.931 |
| Capitalizzazione | 8,014M |
| Beta (5 anni mensile) | 0,94 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -16,4700 |
| Prossima data utili | 15 mag 2024 - 20 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 124,80 |
- GlobeNewswire
NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
Data from the NuTide:701 Study Indicate NUC-7738 May Potentiate the Activity of Anti-PD-1 Agents in Patients who were Refractory to or Progressed on Prior Immunotherapy, including Anti-PD-1 Therapy Several Patients Achieved Reductions in Tumor Volume and Prolonged Time on Treatment BOSTON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced a presentation on the ongoing NuTide:701 study of NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer T
- GlobeNewswire
NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
NUC-3373 Demonstrates Promising Anti-Tumor Activity and a Favorable Safety Profile as part of NUFIRI-bevacizumab and NUFOX-bevacizumab in Second-line Colorectal Cancer Patients Several Second-line Colorectal Cancer Patients in the NuTide:302 Study Achieved a Longer Progression-Free Survival as Compared to Their First-line Treatment with 5-FU-based Therapy NuTide:323 Randomized Study of NUFIRI-bevacizumab vs. FOLFIRI-bevacizumab in Second-Line Colorectal Cancer Patients Recruiting Well with No Ne
- GlobeNewswire
NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
EDINBURGH, United Kingdom, Sept. 18, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced four presentations at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 being held October 11-15, 2023 in Boston, Massachusetts. The details of NuCana’s presentations at the meeting are as follows: Abstract title: NUC-3373 in combination with irinotecan (NUFIRI) or oxaliplatin (NUFOX) and bevacizumab for second-line treatment of patients with adva
